Tom Wade MD

Today, I review, link to, and excerpt from “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [PubMed Abstract] [Full-Text HTML] [Full-Text PDF]. Circulation. 2026 Mar 13. doi: 10.1161/CIR.0000000000001423. Online ahead of print.

All that follows is from the above resource.

Abstract

AIM

The “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia” retires and replaces the “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.”

METHODS

A comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline.

STRUCTURE

The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a).

TABLE OF CONTENTS

Abstract eXXX

What Is New eXXX

Top Take-Home Messages eXXX

Preamble eXXX

1.

Introduction eXXX

1.1.

Methodology and Evidence Review eXXX

1.2.

Organization of the Writing Committee eXXX

1.3.

Relationships With Industry and Other Entities eXXX

1.4.

Peer Review Committee eXXX

1.5.

Scope of the Guideline eXXX

1.6.

Class of Recommendations and Level of Evidence eXXX

2.

Definitions and Classifications eXXX

2.1.

Definitions eXXX

2.2.

Abbreviations eXXX

3.

Evaluation and Diagnosis eXXX

3.1.

Screening in Children and Adults eXXX

3.2.

Measurement of TC, LDL-C, HDL-C, TG, and Non–HDL-C eXXX

3.3.

Measurement of ApoB eXXX

3.4.

Measurement of Lp(a) eXXX

3.5.

Monitoring and Follow-Up eXXX

4.

Management eXXX

4.1.

Lifestyle Management eXXX

4.1.1.

Primordial Prevention of Dyslipidemia: Childhood Through Adulthood eXXX

4.1.2.

Dietary Approaches in Dyslipidemia eXXX

4.1.3.

Attainment and Maintenance of Healthy Weight in People With Dyslipidemia eXXX

4.1.4.

Physical Activity eXXX

4.1.5.

Dietary Supplements eXXX

4.1.6.

When to Refer to a Registered Dietitian Nutritionist eXXX

4.2.

Medical Management eXXX

4.2.1.

Pharmacological Therapy eXXX

4.2.2.

Referring to a Clinical Lipid Specialist eXXX

4.2.3.

Primary Prevention in Adults eXXX

4.2.4.

Severe Hypercholesterolemia (LDL-C ≥190 mg/dL [4.9 mmol/L]) eXXX

4.2.5.

Diabetes in Adults Without Established ASCVD eXXX

4.2.6.

Secondary ASCVD Prevention eXXX

4.2.7.

Management of Adults With Subclinical Coronary Atherosclerosis (Men ≥40 or Women ≥45 Years) eXXX

4.2.8.

Considerations in Patient Management eXXX

4.2.9.

Management of Hypertriglyceridemia eXXX

4.2.10.

Approach to Patients With Elevated Lp(a) eXXX

4.2.11.

Management of Statin-Attributed Muscle Symptoms eXXX

5.

Complications of Management eXXX

5.1.

Medication Safety and Therapy-Associated Side Effects eXXX

5.2.

Statin-Cardiovascular Drug Interactions eXXX

6.

Evidence Gaps and Future Directions eXXX

6.1.

Limitations and Knowledge Gaps eXXX

6.2.

Randomized Controlled Trials eXXX

6.3.

Improving Cardiovascular Risk Assessment eXXX

6.4.

Refining the Clinician–Patient Risk Discussion eXXX

References eXXX

Appendix 1

Writing Committee Relationships With Industry and Other Entities eXXX

Appendix 2

Peer Review Committee Relationships With Industry and Other Entities eXXX